Sam Altman-backed Retro Biosciences is widening its Alzheimer’s trial after early doses showed no red flags. Most drug trials ...

New MOU pairs GlycanAge’s glycan-based biological age test with ExoEarth’s exosome platform, bringing inflammaging testing ...

APLMS will use Singapore, China and India to test how longevity science can translate into function, prevention and healthier ...

Obesity biotech aims to reduce fat while preserving lean mass, with first-in-human studies planned for late 2027.

Leisure exercise lowers dementia risk, while physically demanding jobs may raise it – twist that reshapes how we think about ...

A 350-patient study finds a palm-sized ECG device spots dangerous heart rhythms that hospital-grade monitors miss entirely.

Prevention gets tech budget it deserves as a $499, hour-long body scan backed by Zuckerberg and Sharapova lands in SoHo.

Researchers say disrupted sleep may be one of the earliest signs of Alzheimer’s, arriving years before memory loss and ...

Deal with Singapore’s MuseCell Innovations could bring $300 million in business and 200 jobs to Celularity’s cell platform. Deals in cell therapy tend to get announced in two flavors: the kind built ...

Aesthetics empire opens its first wellness clinic, and it says something about where precision longevity in Southeast Asia is ...

NeuLogiq platform earned high marks from ALS and FTD patients using it at home, addressing a gap left by motor-only rating ...